David M. Nagorney

Active 1981–2025

149
Papers
29,957
Citations
98
h-index
145
i10-index

Citations

Citations per year for David M. Nagorney1975: 1 citations1977: 1 citations1984: 1 citations1985: 2 citations1986: 2 citations1987: 4 citations1988: 7 citations1989: 8 citations1990: 8 citations1991: 17 citations1992: 18 citations1993: 34 citations1994: 37 citations1995: 63 citations1996: 44 citations1997: 63 citations1998: 61 citations1999: 101 citations2000: 99 citations2001: 101 citations2002: 114 citations2003: 144 citations2004: 144 citations2005: 185 citations2006: 232 citations2007: 222 citations2008: 258 citations2009: 223 citations2010: 275 citations2011: 269 citations2012: 245 citations2013: 244 citations2014: 224 citations2015: 232 citations2016: 199 citations2017: 198 citations2018: 128 citations2019: 631 citations2020: 666 citations2021: 540 citations2022: 351 citations2023: 222 citations2024: 397 citations2025: 128 citations1976: no citations, so this year is not shown1978–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,716 citing papers, 27.1% of this breakdownChina: 854 citing papers, 8.5% of this breakdownItaly: 662 citing papers, 6.6% of this breakdownJapan: 565 citing papers, 5.6% of this breakdownUnited Kingdom: 564 citing papers, 5.6% of this breakdownGermany: 558 citing papers, 5.6% of this breakdownFrance: 531 citing papers, 5.3% of this breakdownNetherlands: 375 citing papers, 3.8% of this breakdownSouth Korea: 268 citing papers, 2.7% of this breakdownCanada: 263 citing papers, 2.6% of this breakdownSwitzerland: 234 citing papers, 2.3% of this breakdownSpain: 232 citing papers, 2.3% of this breakdown
0%27.1%Other 22%

Fields

  • Medicine86.1%
  • Biochemistry, Genetics and Molecular Biology11.2%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Immunology and Microbiology0.4%
  • Neuroscience0.4%
  • Computer Science0.3%
  • Other0.9%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis10.6%
  • Cholangiocarcinoma and Gallbladder Cancer Studies9%
  • Pancreatic and Hepatic Oncology Research7.5%
  • Gallbladder and Bile Duct Disorders5.2%
  • Neuroendocrine Tumor Research Advances3.9%
  • Organ Transplantation Techniques and Outcomes3.2%
  • Other60.6%

Coauthors

All papers

Open in search
  1. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

    Authors: , , , , , , , , , , , , , - Annals of Surgery 2019 cited by 437

  2. The International Position on Laparoscopic Liver Surgery

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John B. Martinie, Jean‐Nicolas Vauthey, Robert M. Goldstein, Sasan Roayaie, David Barlet, Joseph Espat, Michaël Abécassis, Myrddin Rees, Yuman Fong, Kelly M. McMasters, Christoph E. Broelsch, Ron Busuttil, Jacques Belghiti, Steven M. Strasberg, Ravi S. Chari - Annals of Surgery 2009 cited by 1,517

  3. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of the National Comprehensive Cancer Network 2022 cited by 57

  4. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

    Authors: , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 1,357

  5. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features

    Authors: , , , , , , , , - Surgery 2019 cited by 142

  6. Diagnosis and Management of Primary Sclerosing Cholangitis

    Authors: , , , , , , - Hepatology 2009 cited by 1,222

  7. Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma

    Authors: , , , , , , , - Annals of Surgery 2005 cited by 686

  8. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study

    Authors: , , , , , , , , , - Journal of the American College of Surgeons 2016 cited by 159

  9. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , - Annals of Surgical Oncology 2021 cited by 65

  10. Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma

    Authors: , , , , , , , , , - Annals of Surgery 2008 cited by 462

  11. Total Laparoscopic Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma

    Authors: , , , , , , - Annals of Surgery 2014 cited by 440

  12. Risk Factors for Mortality After Surgery in Patients With Cirrhosis

    Authors: , , , , , , , , - Gastroenterology 2007 cited by 572

  13. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients

    Authors: , , , , , , , , , , , - Journal of the American College of Surgeons 2023 cited by 41

  14. An APRI+ALBI-Based Multivariable Model as a Preoperative Predictor for Posthepatectomy Liver Failure

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefan Gilg, Alice Assinger, Thomas Gruenberger, Hubert Hackl, Patrick Starlinger - Annals of Surgery 2023 cited by 32

  15. Surgical Treatment of Neuroendocrine Metastases to the Liver

    Authors: , , , , , - Journal of the American College of Surgeons 2003 cited by 771

  16. Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas

    Authors: , , , , , , , , , , , - Oncogene 2002 cited by 482

  17. A Comparison of Routine Cytology and Fluorescence in situ Hybridization for the Detection of Malignant Bile Duct Strictures

    Authors: , , , , , , , , , , , , , - The American Journal of Gastroenterology 2004 cited by 368

  18. The genomic landscape of small intestine neuroendocrine tumors

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2013 cited by 332

  19. Hepatic Resection for Colorectal Metastases

    Authors: , , , , , , - Annals of Surgery 2007 cited by 295

  20. Tumor Size Predicts Vascular Invasion and Histologic Grade

    Authors: , , , , , , , , , , - Liver Transplantation 2005 cited by 638

  21. Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma†

    Authors: , , , , , , , , , , , , , , , , , - Hepatology 2008 cited by 206

  22. Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

    Authors: , , , , , , , , , , , - Annals of Surgical Oncology 2023 cited by 45

  23. Biliary Tract Cancers

    Authors: , , , , - New England Journal of Medicine 1999 cited by 966

  24. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers

    Authors: , , , , , , , , , , , , , , , , - Oncogene 2003 cited by 233